Recursion Pharmaceuticals Summit Therapeutics: 2026 Insight
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
ETH shines with smart contracts and decentralized apps, while BTC remains a store of value and payments option. This overview highlights their use cases.
28,554 articlesTwo biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
This detailed microsoft stock analysis: final verdict breaks down the cloud, AI, and cash flow that power MSFT. Learn...
When a leading fund sells a sizable stake in a cyclical manufacturer after a rough quarter, investors want clarity. T...
This earnings season produced a mix of wins and misses. We break down what worked what didn't, with actionable tips y...
A 3.9% COLA could meaningfully lift a typical Social Security check in 2027. This guide breaks down what that means i...
Investors are watching the Fed for its next move, a key factor in whether GLD can extend its recent 36% rally. Real y...
A tiny AI-focused company has surged roughly 4,000% while still welcoming retail investors. Here’s what’s driving the...
A timely look at Warren Buffett’s Coca-Cola investment and how Berkshire’s KO stake has powered decades of dividend g...
Arm Holdings’ stock has jumped sharply this year on AI data center demand, yet a valuation gap and monetization hurdl...
Fluence Energy surged nearly 100% in a week on big contract wins and a growing backlog. A quartet of AI-exposed energ...
Jim Cramer defies the pullback, urging investors to buy DoorDash despite a roughly 30% year-to-date drop. The call hi...